Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

441 results about "Plasma sample" patented technology

Colorectal cancer early screening method based on multi-omics sequencing

The invention belongs to the technical field of molecular biomedicine, and provides a colorectal cancer early screening method based on multi-omics sequencing, which comprises the following steps: collecting a plasma sample to be detected, collecting sequencing data to be detected, and classifying a colorectal tumor early screening model. The training process of the colorectal tumor early screening model comprises the steps of original sequencing data acquisition, quality control and human reference genome comparison, reference methylation data acquisition, tumor specific region screening, plasma cfDNA sequencing data acquisition, coordinate determination sequencing data acquisition, methylation feature set screening and terminal motif feature screening. And carrying out breakpoint motif feature screening, feature merging and model training. By constructing the colorectal tumor early screening model, the non-invasive colorectal cancer detection method with high cost effectiveness is realized, the economic cost of sequencing is reduced, and the accuracy and sensitivity of detection are remarkably improved.
Owner:THE AFFILIATED SIR RUN RUN SHAW HOSPITAL OF SCHOOL OF MEDICINE ZHEJIANG UNIV

Biomarker method for predicting curative effect of cyclosporine on aplastic anemia

The invention relates to the technical field of aplastic anemia (AA) treatment research, discloses a biomarker method for predicting the curative effect of cyclosporine on aplastic anemia, and aims to detect plasma differential metabolites of patients with aplastic anemia by adopting a metabonomics technology, find potential biomarkers for treating AA patients and find the curative effect of cyclosporine on the AA patients. CsA) is used for treating the in-vivo metabolism of AA. The method is based on liquid chromatography-mass spectrometry (LC-MS) and gas chromatography-mass spectrometry (GC-MS) technologies, and comprises the following steps: collecting 5 plasma samples of AA patients, 5 plasma samples of healthy people and 5 plasma samples of patients in a stable period after treatment for comparative analysis; and screening differential compounds by adopting a multivariate statistical method, and further performing enrichment analysis on differential metabolites. Research of the method shows that in-vivo metabolites of AA patients and healthy people are obviously different, and the way related to immunity and energy metabolism may be a key target for treating AA; csA intervenes the occurrence and development of AA by regulating and controlling immune-related metabolic ways.
Owner:YIXING PEOPLES HOSPITAL

Immunodetection method of multi-index immune checkpoint detection kit

The invention provides an immunodetection method of a multi-index immune checkpoint detection kit, which belongs to the technical field of immunodetection and comprises three main stages of sample preparation, immune reaction and data analysis. The method comprises the following steps: firstly, carrying out centrifugal separation to obtain a plasma sample, and preparing a fluorescent microsphere coupled capture antibody and biotin labeled detection antibody compound; then carrying out immune reaction, forming a sandwich type immune complex through specific binding, and adding streptavidin marked by phycoerythrin for signal amplification. Detecting a fluorescence signal by adopting a flow cytometer to obtain an original data matrix; a contribution feature vector, a utility feature vector and an expression feature matrix are extracted through a feature decomposition algorithm, and a deep learning model of a total-score-total structure is established for data analysis. Finally, a detection report containing a quantitative result, an importance score and reliability evaluation is generated, and the technical problem that in the prior art, the analysis accuracy of a multi-index immune checkpoint detection result is insufficient is solved.
Owner:QINGDAO RAISECARE BIOTECHNOLOGY CO LTD

Application of protein in small extracellular vesicles as prostate cancer diagnostic marker

ActiveCN119125561AHigh AUC valueHigh specificity and sensitivityMaterial analysisAntigenPsa antigen
The invention discloses application of small extracellular endovesicular protein as a prostatic cancer diagnostic marker, and is characterized in that the small extracellular endovesicular protein is plasma sample sEV protein LAMB1 and / or urine sample sEV protein Histone H4, and the plasma sample sEV protein LAMB1 is applied as a metastatic prostatic cancer diagnostic marker. The sEV protein LAMB1 of the plasma sample is combined with a prostate specific antigen to serve as metastatic prostate cancer; the application of the sEV protein Histone H4 in the urine sample as a prostate cancer grading diagnosis marker, the application of the sEV protein Histone H4 in the urine sample as a high-risk prostate cancer diagnosis marker and the application of the combination of the sEV protein Histone H4 in the urine sample and a prostate specific antigen as the high-risk prostate cancer diagnosis marker have the advantages of high sensitivity and strong specificity.
Owner:NINGBO FIRST HOSPITAL

Colorectal cancer early-stage accurate diagnosis model based on plasma cfDNA multi-dimensional fragment omics and construction method and application of colorectal cancer early-stage accurate diagnosis model

The invention discloses a colorectal cancer early-stage accurate diagnosis model based on plasma cfDNA multi-dimensional fragment omics and a construction method and application thereof. The method comprises the following steps: a) collecting and processing a sample; b) performing whole genome sequencing (WGS) and bioinformatics processing; c) fragment omics feature extraction; and d) constructing and optimizing a machine learning model. According to the method, cfDNA is extracted from a plasma sample of a colorectal cancer patient, the fragment size distribution and terminal sequence characteristics of the cfDNA are analyzed by utilizing a high-throughput sequencing technology, and then a specific cfDNA fragment mode related to CRC is identified through bioinformatics analysis. Based on the identified cfDNA fragment features, an economically feasible and highly sensitive diagnosis model is constructed, and early diagnosis of CRC is realized.
Owner:JIANGSU CANCER HOSPITAL

Raw material plasma protein content determination model training method, system, medium and equipment

The invention provides a raw material plasma protein content determination model training method, system, medium and equipment, and relates to the field of protein content determination, and the method comprises the following steps: obtaining a raw material plasma sample and a real protein content label thereof; the method comprises the following steps: acquiring near infrared spectrums of raw material plasma samples based on different temperatures by adopting double sensors to obtain near infrared spectrums containing temperature data; training a CNN-LSTM model, and inputting the near infrared spectrums containing the temperature data into the CNN-LSTM model to obtain a predicted protein content label of each near infrared spectrum; and calculating a loss function of the model according to the predicted protein content label and the real protein content label of each raw material plasma sample, and when the loss of the model is minimum, obtaining a trained CNN-LSTM model. Based on a near infrared spectrum analysis technology and a data fusion strategy, a model is utilized to learn a relationship between spectrum data containing temperature information and real protein content, and the influence of temperature on a protein content detection result is eliminated.
Owner:SHANDONG UNIV

ERNA molecular marker for auxiliary diagnosis of colorectal cancer and application of eRNA molecular marker

The invention discloses an eRNA molecular marker for auxiliary diagnosis of colorectal cancer and application of the eRNA molecular marker, and is characterized in that the eRNA molecular marker is eRNA eCOL4A1, and the nucleotide sequence of the eRNA molecular marker is shown as SEQ ID NO.1. The invention further provides application of the eRNA molecular marker in preparation of a kit for auxiliary diagnosis of colorectal cancer, and the eRNA molecular marker comprises a fluorescent quantitative PCR specific amplification primer for detecting the eRNA eCOL4A1 in a plasma sample, the nucleotide sequence of the upstream primer is 5 '-GGGCAGTGATGTGTAGATGAGTT-3', the nucleotide sequence of the downstream primer is 5 '-TGAACATCACATGGAGC-3', and the kit has the advantages that absolute quantitative detection of target molecules and early screening and identification of colorectal cancer can be rapidly and accurately completed only by a small amount of samples, and the kit is high in sensitivity, high in accuracy and rapid in detection.
Owner:NINGBO FIRST HOSPITAL

Blood concentration detection method, equipment and system for clinical pharmacy

The invention relates to the technical field of optical testing, in particular to a clinical pharmacy-oriented plasma concentration detection method, equipment and system, which comprises the following steps of: acquiring plasma sample spectral data and an image map, determining a waveform characteristic value of each wave crest according to the shape characteristics of the wave crest of the plasma sample spectral data, and determining the waveform characteristic value of each wave crest; acquiring a variation trend and a correlation characteristic of the waveform characteristic value along with the drug concentration, determining the correlation between each wave crest and the blood drug concentration according to the waveform characteristic value of the wave crest, the variation trend and the correlation characteristic of the waveform characteristic value along with the drug concentration, and constructing a histogram of the image map corresponding to each wave crest; determining the contribution degree of each wave crest according to the correlation between each wave crest and the blood drug concentration and the histogram distribution characteristics, performing data dimension reduction on the blood plasma sample spectrum data according to the contribution degree of each wave crest, establishing a detection model, and detecting the blood drug concentration. According to the invention, the complexity of data processing is reduced, and the accuracy and reliability of blood concentration detection are improved.
Owner:SHAANXI NUCLEAR IND 215 HOSPITAL +1

Method, system and device for evaluating glomerular senescence

The invention provides a glomerular senescence evaluation method, system and device, and relates to the technical field of glomerular senescence evaluation.The evaluation method mainly comprises the steps that based on a low-abundance proteomics result of an aged mouse plasma sample, core expression protein related to glomerular senescence is screened out, a prediction model aiming at glomerular senescence is constructed, and the prediction model is used for predicting the glomerular senescence; the prediction model comprises a glomerular senescence index; detecting core expression protein data of a to-be-detected plasma sample, and calculating the glomerular senescence index of the to-be-detected plasma sample according to the prediction model. According to the scheme, aiming at the specificity of glomerular senescence, core expression protein can be screened out and a prediction model can be constructed through methods such as low-abundance proteomics results, so that the glomerular senescence can be evaluated simply, conveniently, reliably and quickly; the scheme is helpful for follow-up efficient research and evaluation of anti-glomerular senescence drugs, and is helpful for follow-up efficient research and explanation of the effect of glomerular senescence in CKD progress.
Owner:GUANGANMEN HOSPITAL CHINA ACAD OF CHINESE MEDICAL SCI

Flurralan content detection method based on cat plasma

A method for detecting the content of fluralana based on cat plasma relates to the technical field of detection of the content of fluralana, and comprises the following steps: extracting fluralana in a cat plasma sample by using an acetonitrile precipitation method, adding isotope deuterium-labeled fluralan-D4 as an internal standard, and quantifying the fluralana by using a UPLC-MS / MS method, verification parameters such as the quantitative range, the minimum quantitation limit, the intra-day and inter-day accuracy and precision of the analyte fluralana in the cat plasma and the selectivity and the recovery rate of the method all meet the requirements; after ULOQ is measured every time, an acetonitrile sample is continuously injected, the analyte residual quantity meets the requirement, the established method for measuring the flurala in the plasma through LC / MS / MS meets the requirement of the related guiding principle, the method is applied to the pharmacokinetics method of the flurala drops in the cat body, and the content of the flurala in the cat plasma sample can be accurately quantified.
Owner:BEIJING GRAND SPARK PHARM TECH CO LTD

A core-shell structure adsorbent, a preparation method and a kit thereof, and a method for detecting the concentration of styrene metabolites in plasma

The invention discloses a core-shell structure adsorbent and a preparation method and a kit thereof, as well as a detection method for the concentration of styrene metabolites in plasma. The core-shell structure adsorbent includes ferroferric oxide magnetic microspheres, petal-shaped titanium dioxide coated on the surface of the ferroferric oxide magnetic microspheres, and a quaternary amine-carbon 18 bifunctionalized oligomeric polymer compound modified on a partial area of ​​the surface of the petal-shaped titanium dioxide. The core of the adsorbent of the present invention is ferroferric oxide magnetic microspheres, and the adsorbent as a whole is magnetic, which can achieve rapid solid-liquid phase magnetic separation, improve the sample purification efficiency, the titanium dioxide component in the material can effectively adsorb the phospholipid components in the plasma, and the quaternary amine-carbon 18 bifunctionalized oligomeric polymer component can effectively adsorb impurities such as fat and inorganic anions in the plasma, thereby effectively reducing the matrix interference effect in the sample detection process, so as to achieve the purpose of quickly and accurately detecting the concentration of trace phenylglyoxylic acid and mandelic acid in the plasma sample.
Owner:NINGBO CENTER FOR DISEASE CONTROL & PREVENTION (NINGBO HEALTH SUPERVISION INSTITUTE NINGBO HEALTH EDUCATION & PROMOTION CENTER)

Methods for detecting RHD incompatibilty in pregnant blood and plasma samples

PCT designated stage expiredWO2025101438A1Microbiological testing/measurementPregnancyPhysiology
Disclosed herein includes a method of detecting RhD incompatibility during pregnancy, comprising: a) extracting DNA from a blood sample of a pregnant mother; b) performing qPCR on the DNA to determine Ct values of at least one RhD exon and at least one internal control gene; and c) calculating a ΔCt value between the at least one RhD exon and at least one internal control gene.
Owner:NATERA INC

Method for determining concentration of human plasma esculentin

The invention discloses a method for measuring the concentration of human plasma esculentin, which comprises the following steps: providing a plasma sample to be measured, and preparing plasma standard curve samples with different concentrations; pretreating a plasma sample; making a standard curve; and testing and calculating the concentration of the esculentin in the to-be-detected plasma sample. According to the invention, deuterated esculentin is used as an interior label. Protein in an epracycline plasma sample is precipitated by using a trifluoroacetic acid-containing methanol aqueous solution. The method comprises the following steps: pre-treating a sample, separating drug components in supernate from the pre-treated sample by using high performance liquid chromatography, then carrying out drug targeting detection by using a high-resolution mass spectrum multi-reaction monitoring mode, and quantifying, so as to realize analysis and determination of the concentration of the esculentin in the plasma. The method disclosed by the invention has the advantages of rapidness, extremely high targeting property, rapidness, high flux, high sensitivity, strong specificity, good precision and accuracy, good stability, high extraction recovery rate and the like. The method disclosed by the invention can be used for monitoring the blood concentration of the elacycline clinically.
Owner:SHANGHAI FIRST PEOPLES HOSPITAL

Plasma exosome separation and extraction device

The invention relates to the technical field of plasma exosome treatment, in particular to a plasma exosome separation and extraction device. The invention aims to solve the technical problems that when an ultracentrifugation method is used for extracting the plasma exosome, the operation is tedious, and the difficulty of operators is increased. According to the technical scheme, the plasma exosome separation and extraction device comprises a centrifugal machine body, the surface of the centrifugal machine body is rotationally connected with a sealing cover through a rotating shaft, and a controller is arranged on the surface of the centrifugal machine body and used for controlling operation in the centrifugal machine. The centrifugal machine has the beneficial effects that the reagent adding mechanism, the sample storage mechanism and the injection mechanism are matched for use, most of tedious operations are replaced by electric programming, an operator is prevented from repeatedly taking out a plasma sample from the centrifugal machine body, the plasma exosome separation and extraction time is shortened, and the operation efficiency is improved. And the operation difficulty of operators is reduced.
Owner:XUZHOU AIWAN MEDICAL LAB CO LTD

Metabolic biomarker for predicting cardiovascular disease risk of senile subclinical hypothyroidism patient and application of metabolic biomarker

The invention relates to a metabolic biomarker for predicting the cardiovascular disease risk of a patient with senile subclinical hypothyroidism and application of the metabolic biomarker. The marker comprises inosine, arachidonic acid, arginine, phenylalanine and glycocholic acid. According to the method, metabolite information of each plasma sample in a research queue is obtained by establishing an elderly SCH and concurrent CVD crowd queue and detecting by adopting a high performance liquid chromatography-mass spectrometry technology, and a targeted metabolic content map is established. According to the matrix expression of the metabolic marker, in combination with clinical follow-up visit data, a model is constructed by using machine learning Lasso-cox, and a clinical prediction model of the CVD risk of the elderly SCH patient is constructed to guide precise diagnosis and treatment of the elderly SCH. The invention further provides a kit containing the diagnostic marker suitable for predicting the CVD risk of the elderly SCH, and the kit can be used for predicting the CVD risk of the elderly SCH.
Owner:NANJING GULOU HOSPITAL GRP SUQIAN HOSPITAL CO LTD

Method for detecting aldosterone, cortisol, deoxycorticosterone and cortisone in plasma by magnetic bead assisted LC-MS / MS

The invention relates to the technical field of medical detection, in particular to a method for detecting aldosterone, cortisol, deoxycorticosterone and cortisone in plasma through LC-MS / MS. The method comprises the following steps: (a) mixing a plasma sample with an internal standard solution to obtain a mixed solution; (b) adding the mixed solution into the magnetic bead suspension, sequentially carrying out adsorption, weak washing, strong washing and elution, and collecting an eluent; (c) carrying out liquid nitrogen blowing and redissolving on the eluent, and then carrying out LC-MS / MS detection; wherein the surfaces of the magnetic beads are modified with steroid adsorption groups, and the target detection objects are aldosterone, cortisol, deoxycorticosterone and cortisone. The detection method is convenient and simple, the detection efficiency is higher than that of a traditional method, and a feasible solution is provided for promoting popularization and application of the LC-MS / MS technology in clinical practice.
Owner:ZHEJIANG PROVINCIAL PEOPLES HOSPITAL

Colorectal cancer plasma circulating microbial marker, reagent, kit and application thereof

The invention discloses a colorectal cancer plasma circulating microbial marker, a reagent, a kit and application thereof, and belongs to the technical field of biomedical detection. The plasma circulating microbial marker for colorectal cancer comprises alternaria alternata, alophilous alophilous alophilous alophilous alophilous alophilous alophilous alophilous alophilous alophilous alophilous alophilous alophilous alophilous alophilous alophilous alophilous alophilous alophilous The colorectal cancer plasma circulating microbial marker can be used for early screening of colorectal cancer, has relatively high sensitivity and specificity, and remarkably improves the accuracy and reliability of detection; the limitation of traditional ctDNA detection is broken through, and the detection rate of early colorectal cancer is improved. The colorectal cancer plasma circulating microbial marker in a colorectal cancer plasma sample is detected through low-depth whole genome sequencing, the requirement for depth in an experiment is reduced, the cost can be greatly reduced while high sensitivity and specificity are guaranteed, and the method is more suitable for large-scale screening.
Owner:BEIJING XUTENG GENE TECHNOLOGY CO LTD

Non-invasive in-vitro method of diagnosis

The invention relates to an in-vitro method of diagnosis, prognosis, treatment response control, response prediction, of a particular human disease comprising the steps of: (i) providing for a human sample, preferably a blood sample from a subject, more preferably a plasma sample, or a serum sample or a buffy coat sample; (ii) preparing a first nucleic acid sequencing library from the nucleic acids present in said sample; (iii) hybridizing one or more TAC oligonucleotides from a first TAC oligonucleotide pool (TAC oligonucleotide-1) to said first nucleic acid library thereby isolating a first subset of library nucleic acid molecules; (iv) sequencing said first subset of library nucleic acid molecules and comparing the sequences determined to a human reference sequence, thereby creating a first group of putatively informative sequence variants (PISV 1); (v) hybridizing one or more TAC oligonucleotides from a second smaller TAC oligonucleotide pool comprising TAG oligonucleotides (TAC oligonucleotide-2) which are specific for the nucleic acid molecules of said first group of putatively informative sequence variants, to said first library of nucleic acid molecules thereby isolating a second subset of library nucleic acid molecules; (vi) sequencing said second subset of library nucleic acid molecules and comparing the sequences determined to a human reference sequence, thereby creating a second group of putatively informative sequence variants (PISV2); (vii) analyzing the putatively informative sequence variants (PISV2) thereby diagnosing, prognosing, controlling the response to a drug, for a particular human disease state. Steps (i) to (iv) are also referred to together as step A. Steps (v) to (vii) are also referred to together as step B.
Owner:MEDICOVER BIOTECH LTD

Non-invasive in-vitro method for somatic mutation detection

The invention relates to an in-vitro method of detecting a somatic mutation in a human comprising the steps of, (i) providing for a human sample, preferably a blood sample from a subject, more preferably a plasma sample, or a serum sample or a buffy coat sample, (ii) preparing a first nucleic acid sequencing library from the nucleic acids present in said sample, (iii) hybridizing one or more TAC oligonucleotides from a first TAC oligonucleotide pool (TAC oligonucleotide-1) to said first nucleic acid library thereby isolating a first subset of library nucleic acid molecules, (iv) sequencing said first subset of library nucleic acid molecules and comparing the sequences determined to a human reference sequence, thereby creating a first group of putatively informative sequence variants (PISV1), (v) hybridizing one or more TAC oligonucleotides from a second smaller TAC oligonucleotide pool comprising TAC oligonucleotides (TAC oligonucleotide-2) which are specific for the nucleic acid molecules of said first group of putatively informative sequence variants, to said first library of nucleic acid molecules thereby isolating a second subset of library nucleic acid molecules, (vi) sequencing said second subset of library nucleic acid molecules and comparing the sequences determined to a human reference sequence, thereby creating a second group of putatively informative sequence variants (PISV2), (vii) analyzing the putatively informative sequence variants (PISV2) thereby detecting a somatic mutation in the sample from the subject. Steps (i) to (iv) are also referred to together as step A. Steps (v) to (vii) are also referred to together as step B.
Owner:MEDICOVER BIOTECH LTD

Method for annotating vesicle cell subpopulation based on single vesicle membrane proteomics

The invention discloses a method for annotating a vesicle cell subset based on monovesicle membrane proteomics, and belongs to the technical field of vesicle cell annotation. The method comprises the following steps: 1, carrying out exosome collection on a plasma sample to obtain a sample; 2, coding and labeling the antibody probe, and adding a protein tag and a labeled DNA sequence into the antibody probe to obtain a labeled antibody probe; 3, preparing a corresponding combined product; 4, adding a labeled antibody probe into the sample to obtain an exosome compound; step 5, capturing an exosome conjugate through CTB; 6, adding the binding product into the exosome conjugate to generate a sequence; 7, constructing a sequence library and sequencing to obtain a sequencing sequence; 8, removing a sequencing sequence with low expression quantity to obtain an exosome expression data matrix, and standardizing the exosome expression data matrix; 9, carrying out clustering analysis to find out an exosome core subgroup; and step 10, determining the source of the exosome core subgroup, and annotating the single vesicle subgroup.
Owner:THE PEOPLES HOSPITAL OF GUANGXI ZHUANG AUTONOMOUS REGION

Blood-based screening of subjects for a clinical trial for treatment of tauopathy or amyloidogenic disease

A method of pre-screening a human subject for a clinical trial for treatment of tauopathy or an amyloidogenic disease. The method comprises obtaining a plasma sample from the subject and determining a concentration of p217+tau present in the plasma sample. The method further comprises indicating the subject for further screening for the clinical trial when the concentration of p217+tau present in the plasma sample is greater than or equal to a minimum threshold and less than or equal to a maximum threshold. The minimum threshold corresponds to an amount of p217+tau in plasma over which subjects present with mild cognitive impairment (MCI) and an increased accumulation of tau tangles in the brain as compared to a cognitively normal patient. The maximum threshold corresponds to an amount of p217+tau present in plasma over which subjects present with pathology of widespread accumulation of tau tangles in multiple regions of the brain.
Owner:JANSSEN PHARMA NV

Metabolic marker combination for ovarian cancer diagnosis and application thereof

The invention provides a metabolic marker combination for ovarian cancer diagnosis and application thereof, and belongs to the technical field of in-vitro diagnosis. The invention provides a metabolic marker combination for ovarian cancer diagnosis. The metabolic marker combination comprises phosphatidylcholine 34: 4, threonic acid, phosphatidylcholine 32: 2, pyroglutamic acid, phosphatidylcholine 36: 6 and ceramide d38: 2. According to the metabolic marker combination, plasma samples of a healthy subject and an ovarian cancer patient are analyzed, a group of biomarkers with significant difference are screened from the plasma samples, and the metabolic marker combination is a non-invasive, non-invasive and high-accuracy metabolic marker combination for distinguishing the healthy subject and the ovarian cancer patient. The method can be used for constructing a diagnostic model for distinguishing healthy subjects from ovarian cancer patients. The metabolic marker combination disclosed by the invention can be used for improving the diagnosis and evaluation capability of ovarian cancer patients, so that early discovery, early diagnosis and early intervention can be realized clinically, and the survival rate of the ovarian cancer patients is improved.
Owner:HARBIN METANOTITIA INC

Application of LPC, PC and AA in children sepsis diagnosis and prognosis product development

The invention relates to the field of biological medicine, and discloses application of LPC, PC and AA in children sepsis diagnosis and prognosis product development. According to the invention, a high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS / MS) technology is used, plasma samples of a child sepsis patient and a healthy control group are compared, the relationship between lipidome change and pSOFA score is analyzed, and specific lipid molecules closely related to disease severity and prognosis are identified. According to the invention, the following lipid molecules are highlighted as key biomarkers: lysophosphatidylcholine (LPC), phosphatidylcholine (PC) and arachidonic acid (AA). The change of the lipid molecules is closely related to the physiological state of a child sepsis patient, and the lipid molecules can be used for early diagnosis and evaluation of the state of the child sepsis, so that the treatment effect and the accuracy of prognosis evaluation are improved, and a new treatment strategy and a new management method are provided for clinic.
Owner:ANHUI PROVINCIAL CHILDRENS HOSPITAL (ANHUI XINHUA HOSPITAL ANHUI INST OF PEDIATRIC MEDICINE FUDAN UNIV CHILDRENS HOSPITAL ANHUI HOSPITAL)

Novel high performance liquid chromatography-tandem mass spectrometry analysis method for detecting aspartatide in human plasma

The invention discloses a novel high performance liquid chromatography-tandem mass spectrometry analysis method for detecting aspartatide in human plasma, teriparatide is used as an internal standard substance to be detected, a solid phase extraction method is adopted to extract aspartatide to be detected and internal standard teriparatide from a plasma sample, and a standard curve is linear in a range of 0.010-1.00 ng / mL. During the verification of the method, selectivity, matrix effect, recovery, sensitivity, linearity, accuracy and precision, stability and dilution reliability are assessed to meet standards. The method disclosed by the invention has specificity on determination of the to-be-detected substance, i.e., the aspartatide and the internal standard teriparatide in the human plasma, and a standard curve is linear in a range of 0.010-1.00 ng / mL. The quantitative lower limit of methodology is 0.01 ng / mL. The method has the advantages of good accuracy, reliability, high sensitivity, high specificity and reproducibility.
Owner:JUNKE ZHENGYUAN (SHANGHAI) BIOMEDICAL TECH CO LTD

Lateral flow immunoassay for measuring functional c1-esterase inhibitor (c1-INH) in plasma samples

A device for detecting and / or quantifying functional C1-esterase inhibitor (fC1-INH), the device comprising: (i) a conjugate pad comprising a first zone and a second zone, on which a first agent and a second agent are immobilized, respectively, and (ii) a membrane, which is in communication with the conjugate pad, wherein the membrane comprises a third zone, on which a third agent is immobilized. The conjugate pad may further comprise a fourth zone for placing a biological sample, which flows through the device in the order of the first zone, the second zone, and the third zone.
Owner:TAKEDA PHARMA CO LTD

Antinuclear antibody spectrum quality control product as well as preparation method and application thereof

The invention belongs to the technical field of in-vitro diagnosis, and particularly relates to an antinuclear antibody spectrum quality control product as well as a preparation method and application thereof. The preparation method of the antinuclear antibody spectrum quality control product comprises the following steps: providing a plasma sample containing an antinuclear antibody as a raw material, and screening a co-positive raw material as a to-be-concentrated raw material; performing ultrafiltration concentration on the to-be-concentrated raw material to prepare an antibody solution; and mixing the antibody solution with a protective solution to obtain the antinuclear antibody spectrum quality control product. The invention mainly aims to provide the antinuclear antibody spectrum composite quality control product with analysis performance and stability meeting clinical examination requirements, the antinuclear antibody spectrum composite quality control product is adaptive to an immunoblotting reagent platform of a mainstream manufacturer, 15 detection items of an antinuclear antibody spectrum can be covered by the antinuclear antibody spectrum composite quality control product, subsequent efficient and rapid detection can be performed through an immunoblotting method, and the detection efficiency is greatly improved. Therefore, the aim of controlling the quality of the antinuclear antibody spectrum composite project is fulfilled.
Owner:SHENZHEN ZHAOLAN BIOTECHNOLOGY CO LTD

Diabetic nephropathy risk prediction method and system based on protein markers

The invention relates to the field of medical informatics, and provides a diabetic nephropathy risk prediction method and system based on a protein marker. The method comprises the following steps: detecting the concentration of a protein marker in a plasma sample of a diabetic to obtain plasma protein marker concentration data; performing longitudinal correlation analysis on the protein markers according to the plasma protein marker concentration data to obtain the kidney disease related protein markers; performing feature screening on the kidney disease related protein marker combination to obtain a core protein marker; establishing a nephropathy risk prediction model through the clinical parameters of the diabetic patient and the core protein marker combination; and outputting a nephropathy risk prediction result of the patient to be detected through the nephropathy risk prediction model. The advanced intervention of the diabetic nephropathy is realized, and the prediction accuracy of the diabetic nephropathy is improved.
Owner:BEIJING CHAOYANG HOSPITAL CAPITAL MEDICAL UNIVERSITY

Nucleic acid error suppression

Nucleic acid error suppression is provided. In various embodiments, DNA is extracted from a collection of plasma samples. A sequence library with duplex adapters is prepared by ligating a duplex adapter having a Unique Molecule Identifier (UMI) to an end of each of a plurality of strands of the extracted DNA and amplifying the extracted DNA with a first polymerase chain reaction (PCR). A subset of the whole genome library is selected and amplified with a second PCR to increase an amount of PCR duplicates. A plurality of duplex reads is sequenced from the amplified subset aligned to a host genome and denoised based on said alignment. A variant presence is detected in at least one of the plurality of duplex reads. A signature of the variant is determined, which is compared to a collection of disease-specific variant signatures. A disease type is determined based on the comparison.
Owner:CORNELL UNIVERSITY

Plasma proteome-based colorectal cancer precancerous lesion diagnosis model construction method

PendingCN119724556AMedical data miningBiostatisticsLesion progressionOncology
The invention discloses a plasma proteome-based colorectal cancer precancerous lesion diagnosis model construction method, and aims to solve the problem that a current colorectal cancer diagnosis kit is insufficient in sensitivity and specificity when detecting an early stage (precancerous lesion / early cancer) through a proximity extension technology (PEA) and selecting a specific detection panel. Protein biomarkers in plasma samples of 80 patients with precancerous lesion (progression stage adenoma) and early cancer (Tis / T1 stage) in a discovery queue are identified. By adjusting potential clinical confounding factors, 15 key protein biomarkers are identified. In the discovery queue, four machine learning algorithms (Lasso regression, random forest, SVM and XGBoost) are adopted to diagnose early colorectal cancer lesions, and high diagnosis efficiency is realized through multiple machine learning algorithms. In a verification queue sample, the diagnosis model also shows an important diagnosis capability for patients with progression-stage adenoma or early-stage colorectal cancer, and has a potential clinical application value.
Owner:WEST CHINA HOSPITAL SICHUAN UNIV

Brain-derived Tau protein single-molecule fluorescence immunoassay detection kit and use method thereof

The invention discloses a brain-derived Tau protein single-molecule fluorescence immunoassay detection kit and a use method, the kit provided by the invention is composed of a BD-Tau magnetic bead reagent coated with a capture antibody, a BD-Tau calibrator, a BD-Tau quality control product, a biotinylated BD-Tau Detector reagent for detecting the antibody, a BD-Tau SBG reagent, an RGP reagent and a BD-Tau sample diluent, the magnetic bead concentration of the BD-Tau magnetic bead reagent is 0.04 mg / mL-0. 08mg / mL of carboxyl magnetic beads, the carboxyl magnetic beads are coated with Tau J5.H3 coated antibodies, the detection antibody in the BD-Tau Detector reagent of the biotinylated detection antibody is Tau12, the concentration of the detection antibody is 0.3 mu g / mL-0. 8mu g / mL, and the concentration of SBG in the BD-Tau SBG reagent is 40 pM-60 pM; the kit disclosed by the invention can be used by adopting any one of a one-step method, a two-step method or a three-step method to detect the content of the BD-Tau protein in a plasma sample, the detection limit is 0.050 pg / mL, and the detection range is 0.050 pg / mL-150 pg / mL; according to the invention, the specificity, accuracy and reliability of determination of the Alzheimer's disease are improved, and the problems of early diagnosis and early screening of the Alzheimer's disease are solved.
Owner:YOUDA BIOTECHNOLOGY (SHIJIAZHUANG) CO LTD